Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin | Zendy

Daniel M. Hartung | Zendy; Kirbee Johnston | Zendy; David Cohen | Zendy; Thuan Nguyen | Zendy; Atul Deodhar | Zendy; Dennis Bourdette | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin

Author(s) -

Daniel M. Hartung,

Kirbee Johnston,

David Cohen,

Thuan Nguyen,

Atul Deodhar,

Dennis Bourdette

Publication year - 2018

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.0482

Subject(s) - mallinckrodt , payment , medicaid , medical prescription , medicine , family medicine , pharmacy , finance , business , nursing , health care , economics , economic growth

Key Points Question What is the association of industry payments to physicians and prescriptions for repository corticotropin (H. P. Acthar Gel; Mallinckrodt Pharmaceuticals)? Findings In this cross-sectional study of 235 specialist physicians who frequently prescribe corticotropin to Medicare beneficiaries, 207 (88%) received a monetary payment from the drug’s maker, with more than 20% of frequent prescribers receiving more than $10 000. There was a significant association between higher dollar amounts paid to these prescribers and greater Medicare spending on their corticotropin prescriptions. Meaning Financial conflicts of interest among physicians may be driving corticotropin expenditures for the Medicare program.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research